首页>
外国专利>
Therapeutic use of novel pharmaceutical formulations containing antitumor drugs conjugated to hyaluronic acid in the treatment of tumors
Therapeutic use of novel pharmaceutical formulations containing antitumor drugs conjugated to hyaluronic acid in the treatment of tumors
展开▼
机译：含有与透明质酸结合的抗肿瘤药物的新型药物制剂在肿瘤治疗中的治疗用途
展开▼
页面导航
摘要
著录项
相似文献
摘要
The present invention describes the new use in the oncologic field of bioconjugates as differentiating agents obtained by the conjugation between hyaluronic acid (HA) and a chemotherapeutic product (identified hereafter with the trade-name ONCOFID®) among which, in particular, Irinotecan, Doxorubicin, Paclitaxel, Cis-platinum and 5-Fluorouracyl (5-FU) for treating primary tumors and metastasis. In particular, the biological behavior is described in terms of action mechanism, efficacy and tolerability of pharmaceutical preparations of derivative of ONCOFID® soluble in water. More specifically, the invention relates to the surprising biological and pharmacological effect demonstrated by formulations based on ONCOFID-S (HA-SN38 conjugates) and ONCOFID-D (HA-Doxorubicin conjugates) in promoting the differentiation of tumoral cells towards a untransformed phenotype, compared with the reference drug Irinotecan (or CPT11 whose active form is represented by SN38) and Doxorubicin.
展开▼
